1. Generics Bulletin
  2. >>Products

Teva Launches ProAir Dry Powder Digital Inhaler

Teva’s First Generic Of Merck Sharpe & Dohme Is For Asthma & COPD Patients

 
• By Akriti Seth

After getting FDA approval in 2018, Teva finally launches its ProAir Digihaler. The company will be making its complete ‘Digihaler’ portfolio available in the US by prescription later this year.

Inhaler
After Cipla & Perrigo, Teva announces launch of albuterol sulfate inhalation powder • Source: Shutterstock

Teva Pharmaceuticals USA Inc.has announced the launch of “the first and only digital rescue inhaler,” its ProAir Digihaler (albuterol sulfate), which received approval from the US Food and Drug Administration in December 2018.

Commenting on the launch, Brendan O’Grady, executive vice president of North America commercial at Teva, said, “The launch of ProAir Digihaler and its companion app provides a great opportunity for

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.